HC Wainwright reiterated their buy rating on shares of IO Biotech (NASDAQ:IOBT – Get Rating) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for IO Biotech’s Q1 2023 earnings at ($0.74) EPS, Q2 2023 earnings at ($0.82) EPS, Q3 2023 earnings at ($0.93) EPS, Q4 2023 earnings at ($1.04) EPS, FY2023 earnings at ($3.54) EPS, FY2024 earnings at ($2.15) EPS, FY2025 earnings at ($1.52) EPS, FY2026 earnings at ($1.15) EPS and FY2027 earnings at ($0.79) EPS.
Separately, Morgan Stanley dropped their price objective on IO Biotech from $15.00 to $11.00 and set an overweight rating on the stock in a research note on Tuesday, January 24th.
IO Biotech Stock Performance
IO Biotech stock opened at $1.98 on Wednesday. The stock’s fifty day moving average is $2.60 and its two-hundred day moving average is $2.67. IO Biotech has a fifty-two week low of $1.91 and a fifty-two week high of $9.77. The firm has a market capitalization of $39.05 million, a price-to-earnings ratio of -0.80 and a beta of -0.61.
Institutional Investors Weigh In On IO Biotech
IO Biotech Company Profile
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
- Get a free copy of the StockNews.com research report on IO Biotech (IOBT)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.